Pulmonary fibrosis (PF) is a devastating disease characterized by remodeling of lung architecture and abnormal deposition of fibroblasts in parenchymal tissue and ultimately results in respiratory failure and death. Preclinical studies suggest that mesenchymal stem cell (MSC) administration may be a safe and promising option in treating PF. The objective of our meta-analysis is to assess the efficacy of MSC therapy in preclinical models of PF. We performed a comprehensive literature search in PubMed, EMBASE, Web of Science, and Cochrane Library databases from inception to March 17, 2021. Studies that assessed the efficacy of MSC therapy to animals with PF were included. The SYRCLE bias risk tool was employed to evaluate the bias of included studies. The primary outcomes included survival rate and pulmonary fibrosis scores. Meta-analysis was conducted via Cochrane Collaboration Review Manager (version 5.4) and Stata 14.0 statistical software. A total of 1120 articles were reviewed, of which 24 articles met inclusion criteria. Of these, 12 studies evaluated the survival rate and 20 studies evaluated pulmonary fibrosis scores. Compared to the control group, MSC therapy was associated with an improvement in survival rate (odds ratios (OR) 3.10, 95% confidence interval (CI) 2.06 to 4.67, P < 0.001, I2 = 0%) and a significant reduction in pulmonary fibrosis scores (weighted mean difference (WMD) 2.05, 95% CI −2.58 to −1.51, P < 0.001, I2 = 90%). MSC therapy is a safe and effective method that can significantly improve the survival and pulmonary fibrosis of PF animals. These results provide an important basis for future translational clinical studies.

中文翻译：

---

肺纤维化中的间充质干细胞治疗：临床前研究的荟萃分析

肺纤维化 (PF) 是一种破坏性疾病，其特征是肺结构的重塑和实质组织中成纤维细胞的异常沉积，最终导致呼吸衰竭和死亡。临床前研究表明，间充质干细胞 (MSC) 给药可能是治疗 PF 的一种安全且有前景的选择。我们荟萃分析的目的是评估 MSC 治疗在 PF 临床前模型中的疗效。从开始到 2021 年 3 月 17 日，我们在 PubMed、EMBASE、Web of Science 和 Cochrane 图书馆数据库中进行了全面的文献搜索。包括评估 MSC 治疗对 PF 动物的疗效的研究。SYRCLE 偏倚风险工具用于评估纳入研究的偏倚。主要结果包括存活率和肺纤维化评分。Meta 分析通过 Cochrane Collaboration Review Manager（5.4 版）和 Stata 14.0 统计软件进行。共审查了 1120 篇文章，其中 24 篇符合纳入标准。其中，12 项研究评估了存活率，20 项研究评估了肺纤维化评分。与对照组相比，MSC 治疗与生存率的提高有关（优势比 (OR) 3.10，95% 置信区间 (CI) 2.06 至 4.67，P < 0.001，I2 = 0%）和肺纤维化评分（加权平均差 (WMD) 2.05，95% CI -2.58 至 -1.51，P < 0.001，I2 = 90%）。MSC疗法是一种安全有效的方法，可以显着提高PF动物的存活率和肺纤维化。这些结果为未来的转化临床研究提供了重要的基础。